[Translated Article] Disease-modifying treatments for patients with multiple sclerosis in Spain
CONCLUSIONS: We have described the disease-modifying treatment of patients with multiple sclerosis seen in Spanish pharmacy services and characterized concomitant treatments, the prevalence of polypharmacy, interactions, and their complexity.PMID:37394376 | DOI:10.1016/j.farma.2023.05.005 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - July 2, 2023 Category: Drugs & Pharmacology Authors: Alejandro Santiago P érez Santos Esteban Casado Miriam Álvarez Payero Ángel Escolano Pueyo Ángel Guillermo Arévalo Bernabé N úria Padullés Zamora Pilar Diaz Ruiz Ana Mar ía López González Source Type: research
A safety review of current monoclonal antibodies used to treat multiple sclerosis
This article reviews the literature on the use of mAbs for the treatment of MS, including their mechanisms of action, clinical trial data, safety profiles, and long-term outcomes. The review focuses on the three main categories of mAbs used in MS: alemtuzumab, natalizumab, and anti-CD20 drugs. A literature search was conducted using relevant keywords and guidelines and reports from regulatory agencies were reviewed. The search covered studies published from inception to 31 December 2022. The article also discusses the potential risks and benefits of these therapies, including their effects on infection rates, malignancies,...
Source: Expert Opinion on Drug Safety - June 14, 2023 Category: Drugs & Pharmacology Authors: Gloria Dalla Costa Giancarlo Comi Source Type: research
Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world
CONCLUSIONS: This analysis provides insights on PML in patients receiving natalizumab that extend current knowledge, particularly regarding PML in patients receiving natalizumab EID, which can be built upon in the future.PMID:37272350 | DOI:10.1080/14740338.2023.2221027 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - June 5, 2023 Category: Drugs & Pharmacology Authors: Liesel Dsilva Kerry McCarthy Jennifer Lyons Bernadette Cabigas Nolan Campbell George Kong Bryan Adams Robert Kuhelj Priya Singhal Karen Smirnakis Source Type: research
Refractory Eosinophilic Fasciitis: Good Response to Ocrelizumab in a Patient With Multiple Sclerosis Under Treatment With Natalizumab
Actas Dermosifiliogr. 2023 Jun 3:S0001-7310(23)00417-9. doi: 10.1016/j.ad.2023.02.023. Online ahead of print.NO ABSTRACTPMID:37276994 | DOI:10.1016/j.ad.2023.02.023 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - June 5, 2023 Category: Dermatology Authors: B V ázquez Losada M Garc ía Martínez W J Villafani Echazu Y Hidalgo Garc ía Source Type: research
Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world
CONCLUSIONS: This analysis provides insights on PML in patients receiving natalizumab that extend current knowledge, particularly regarding PML in patients receiving natalizumab EID, which can be built upon in the future.PMID:37272350 | DOI:10.1080/14740338.2023.2221027 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - June 5, 2023 Category: Drugs & Pharmacology Authors: Liesel Dsilva Kerry McCarthy Jennifer Lyons Bernadette Cabigas Nolan Campbell George Kong Bryan Adams Robert Kuhelj Priya Singhal Karen Smirnakis Source Type: research
Refractory Eosinophilic Fasciitis: Good Response to Ocrelizumab in a Patient With Multiple Sclerosis Under Treatment With Natalizumab
Actas Dermosifiliogr. 2023 Jun 3:S0001-7310(23)00417-9. doi: 10.1016/j.ad.2023.02.023. Online ahead of print.NO ABSTRACTPMID:37276994 | DOI:10.1016/j.ad.2023.02.023 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - June 5, 2023 Category: Dermatology Authors: B V ázquez Losada M Garc ía Martínez W J Villafani Echazu Y Hidalgo Garc ía Source Type: research
Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world
CONCLUSIONS: This analysis provides insights on PML in patients receiving natalizumab that extend current knowledge, particularly regarding PML in patients receiving natalizumab EID, which can be built upon in the future.PMID:37272350 | DOI:10.1080/14740338.2023.2221027 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - June 5, 2023 Category: Drugs & Pharmacology Authors: Liesel Dsilva Kerry McCarthy Jennifer Lyons Bernadette Cabigas Nolan Campbell George Kong Bryan Adams Robert Kuhelj Priya Singhal Karen Smirnakis Source Type: research
Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
(Source: Journal of Neurology)
Source: Journal of Neurology - June 5, 2023 Category: Neurology Source Type: research
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation
This cohort study investigates differences in the effectiveness and treatment persistence between dimethyl fumarate, fingolimod, and ocrelizumab among patients with relapsing-remitting multiple sclerosis who switched from natalizumab. (Source: JAMA Neurology)
Source: JAMA Neurology - June 5, 2023 Category: Neurology Source Type: research
Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis
Conclusion: The most efficacious DMTs for RMS were mAb therapies. Of the newer therapies, only ublituximab ranked among the three most efficacious treatments (for ARR).PMID:37265062 | DOI:10.57264/cer-2023-0016 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - June 2, 2023 Category: General Medicine Authors: Imtiaz A Samjoo Christopher Drudge Sarah Walsh Santosh Tiwari R óisín Brennan Ibolya Boer Dieter A H äring Luisa Klotz Nicholas Adlard Judit Banhazi Source Type: research
